Sutro Biopharma, Inc.: Form 10-K for the period ended Dec 31, 2018
Filed with the SEC on Apr 1, 2019 and accepted by EDGAR at Mar 29, 2019, 19:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-10-02 to 2018-12-31 | $19.1m | us-gaap:Revenues |
| Research and development | 12 months2018-01-01 to 2018-12-31 | $54.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2018-01-01 to 2018-12-31 | −$37.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2018-01-01 to 2018-12-31 | $1.6m | us-gaap:InterestExpense |
| Income tax | 12 months2018-01-01 to 2018-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-10-02 to 2018-12-31 | −$1.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2018-01-01 to 2018-12-31 | −$35.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-10-02 to 2018-12-31 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2018-01-01 to 2018-12-31 | −$6.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | $12.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-12-31 | $125.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-12-31 | $209.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $223.1m | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $36.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-12-31 | $91.6m | us-gaap:Liabilities |
| Long-term debt | At period end2018-12-31 | $10.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-12-31 | $4.7m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2018-12-31 | $131.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-19-010253. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.